1. Home
  2. CTRM vs HOWL Comparison

CTRM vs HOWL Comparison

Compare CTRM & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castor Maritime Inc.

CTRM

Castor Maritime Inc.

HOLD

Current Price

$2.44

Market Cap

21.6M

ML Signal

HOLD

Logo Werewolf Therapeutics Inc.

HOWL

Werewolf Therapeutics Inc.

HOLD

Current Price

$0.89

Market Cap

17.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTRM
HOWL
Founded
2016
2017
Country
Cyprus
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.6M
17.9M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
CTRM
HOWL
Price
$2.44
$0.89
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.00
AVG Volume (30 Days)
34.1K
527.6K
Earning Date
04-15-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
18.40
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.66
$0.27
52 Week High
$2.65
$2.23

Technical Indicators

Market Signals
Indicator
CTRM
HOWL
Relative Strength Index (RSI) 70.02 86.44
Support Level $2.01 $0.80
Resistance Level $2.65 $1.01
Average True Range (ATR) 0.12 0.04
MACD 0.04 0.03
Stochastic Oscillator 100.00 78.40

Price Performance

Historical Comparison
CTRM
HOWL

About CTRM Castor Maritime Inc.

Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under three reportable segments, namely (i) the dry bulk segment, (ii) the containership segment, and (iii) the asset management segment. It generates maximum revenue from the Dry bulk segment.

About HOWL Werewolf Therapeutics Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.

Share on Social Networks: